Current Size: 100%


BMBWF supports development of vascularized skin grafts


Since 2021, the FWF is offering the funding program "Alternative methods for animal experiments" with funds from the Federal Ministry of Education, Science and Research (BMBWF). The aim of the program is to enable Austrian research projects, that contribute to the 3Rs: reducing, replacing and refining animal experiments to lessening the burden on animals.

One of the top projects that were able to prevail in international assessments due to their excellence is a project by the Ludwig Boltzmann Research Group: Senescence and Healing of Wounds (ShoW). The LBI Trauma acts as host and close cooperation partner of the research group.

A life dedicated to trauma research


Head of the institute, chair of TERMIS Europe, founder of the Austrian Cluster for Tissue Regeneration…. Heinz Redl has achieved a lot in his scientific career - and is far from done yet. In an interview with he looks back at the greatest successes and gives insights into his fascination with tissue regeneration and the future of trauma research. The article was published in the current issue and is accessible online here (German only).

Dr. Marcin Osuchowski elected president of the European Shock Society


Marcin Osuchowski, head of Intensive Care Research at LBI Trauma, has been recently elected to serve as the next president of the European Shock Society (ESS). He will hold the office from 2022 to 2023. Given that each incoming president is automatically tasked with organizing a biennial ESS conference, Dr. Osuchowski’s function will result in bringing the top “shock-crowd” to Vienna for a vibrant meeting in 2023!

New guidelines for sepsis studies - MQTiPSS are gaining attention


The incidence of sepsis is on the rise worldwide. Despite continuous improvements of diagnosis and treatment, one out of four hospitalized septic patients dies of the condition. While patient management is organized by up-to-date guidelines, the translation of new research findings into the clinics is hampered by the lack of best practices and standardization in preclinical sepsis studies. With large quality gaps as well as conflicting data, scientists struggle to reconcile the pre-existing and emerging experimental findings into coherent blueprints of sepsis pathophysiology.

Rejuvenating the leadership at LBI Trauma


For the past 20 years the institute was led by Heinz Redl. Although he can look back on an impressive carrier, he likes to shift the attention away from himself and towards research. “Art is I, Science is We” The quote from Claude Bernard, pinned to his office door, reminds visitors of his motto. The Austrian Cluster for Tissue Engineering is just one example of his ongoing efforts for collaboration and cooperation within the scientific community.

Marcin Osuchowski will speak at the opening session of the 9th “Sepsis Update” International Congress


Dr. Marcin Osuchowski, the head of Intensive Medicine (and sepsis research group) at LBI Trauma, has recently been invited to the 2019’s “Sepsis Update” Congress on sepsis and multi-organ dysfunction attended by the Who is Who in the international sepsis community. Dr.  Osuchowski, together with Drs. Singer, Angus and Weigand, will cover topics centered on the main theme of this year’s congress: “Tribute to Translation”. Specifically, Dr. Osuchowski will discuss utility of preclinical models in sepsis research with a talk titled “Quality thresholds in preclinical sepsis models”.

The eye of the beholder – histological image wins photo competition


Scientific results are evaluated based on objective criteria, while beauty lies in the eye of the beholder. Time and again research yields images which are perceived as beautiful, yet this subjective aspect is often overlooked. A contest organized by the MuSkITYR aimed to bring them into the spotlight. Under the headline Science meets Art they were looking for images from the field of musculoskeletal research which they jury then assessed for their artistic value.

Decreased death rate due to improved coagulation


Coagulopathies – conditions in which the blood’s ability to form clots is impaired – occur in one quarter of patients at the intensive care unit, with often life-threatening consequences. They are caused by high blood loss or reactions following systemic shock, but also previous intake of anticoagulants. Hemostasis and wound closure are vitally important as soon as possible after injury. To counteract coagulopathies blood transfusion in high amounts used to be the treatment of choice. However, blood products are valuable (because essential for the treatment of certain pathologies) and may cause unwanted side effects.